An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Stereotaxis announced that the recent BBC documentary "From the Heart" included a cardiac ablation procedure performed with the Stereotaxis System by Dr. Muchtiar Khan of OLVG Hospital in Amsterdam. The program's second half, beginning at 10:30 of the 25-minute run time, features extensive scenes from the Stereotaxis procedure.
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”
Next month, in the Norwegian town of Rena, 12,000 elite cross-country skiers will line up for this year's Birkebeiner ski marathon, an annual endurance race which will take them through 54 kilometres of snow-covered countryside to the winter sports resort of Lillehammer.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
CardioNet, Inc. announced today that the 300,000th patient has been monitored with the Company’s Mobile Cardiac Outpatient Telemetry (MCOT™) service. MCOT is the first system to provide real-time wireless ECG monitoring and 24/7/365 analysis and response.
A surgeon and an electrophysiologist in the Methodist DeBakey Heart & Vascular Center last week worked together to perform a novel, minimally-invasive procedure to treat a common but dangerous arrhythmia in a 61-year-old lawyer from east Texas who has suffered from the condition for months.
St. Jude Medical, Inc. today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the IRASE AF (IRrigated Ablation System Evaluation for AF) trial, a multicenter, randomized, single-blind study evaluating the safety and efficacy of the company’s Duo 12 port open irrigated catheter ablation system for treatment of Atrial Fibrillation (AF). AF is the most common cardiac arrhythmia (abnormal heartbeat), affecting an estimated 3.3 million Americans and millions more worldwide.
Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.
Lebanon Cardiology Associates teamed with The Good Samaritan Hospital to implement one of the top 15% performing emergency cardiac catheterization teams treating heart attacks in the United States.
The portable magnetometer is being developed at the University of Leeds, with funding from the Engineering and Physical Sciences Research Council (EPSRC) playing a key role.
Even healthy people exposed to ultrafine particulate pollution associated with traffic and fossil-fuel combustion for just two hours show changes in heart rhythm and evidence of clot formation that may herald the potential for serious cardiac events, according to research from the Environmental Protection Agency.
UCLA researchers have discovered that a specific type of medication used to treat cardiovascular conditions such as hypertension, angina and abnormal heart rhythms may also decrease the risk of developing Parkinson's disease.
Ushering in a new era in comprehensive cardiac care, the Vivian and Seymour Milstein Family Heart Center celebrated its opening today at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has received FDA approval of its PMA (Pre-Market Approval) supplement, allowing the use of its HeartMate II LVAS (Left Ventricular Assist System) for Destination Therapy (DT).
National medical and lifestyle experts have been brought together by sanofi-aventis U.S. to help aging Americans learn to live life more fully despite a serious and increasingly prevalent heart condition – atrial fibrillation (AFib), a type of irregular heartbeat.
The sporting world lost two young athletes this month to sudden cardiac death. Preliminary autopsy reports indicate that Chicago Bears defensive end Gaines Adams, 26, and Southern Indiana center Jeron Lewis, 21, both had enlarged hearts at the time of their death.
Scientists at the University of Leicester are 'painting' the colours of the heart in an innovative project that has potential to bring benefits for millions of people with irregular heart rhythm.
Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANT™ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.
Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.